Expanding Minimally Invasive Treatment Through Innovative Products for CTO Treatment
First written in FY2016. 3 of 9 entries say "Cited as achieved", first in FY2017-Q3. Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「PRISMbros is a guidewire that uses the ExtRAND coil technology adopted in the GAIA Next series. It is designed for use even when the vessel course is unclear, enabling safer and more accurate crossing of CTO lesions.」
We developed PRISMbros for CTO lesions using ExtRAND coil technology, advancing the development of products for highly challenging procedures. - FY2025SoftenedAnnual report
「The Plasma Wire System, which we had been developing for many years as a next-generation CTO penetration device in the cardiovascular field, completed an exploratory clinical trial last year and was being prepared for a confirmatory clinical trial, but we abandoned its development for business reasons.」
Although the policy of developing innovative products for CTO treatment remains in place, development of the Plasma Wire System, which had been developed as a next-generation CTO penetration device, was abandoned for business reasons. - FY2021RestatedAnnual report
「As a research and development-driven company, we will continue developing and commercializing highly competitive, innovative products and new products with enhanced functionality, thereby contributing to the adoption and advancement of minimally invasive treatment.」
The company is reaffirming its policy of contributing to the adoption of minimally invasive treatment through the continued development of innovative products and new products. - FY2019RestatedAnnual report
「As a research and development-driven company, we will continue developing and commercializing highly competitive, innovative products and new products with enhanced functionality, thereby contributing to the adoption and advancement of minimally invasive treatment.」
The company is reaffirming its policy of contributing to the adoption of minimally invasive treatment through the continued development of innovative products and new products. - FY2018RestatedAnnual report
「As a research and development-driven company, we will continue developing and commercializing highly competitive, innovative products and new products with enhanced functionality, thereby contributing to the adoption and advancement of minimally invasive treatment.」
The company is reaffirming its policy of contributing to the adoption of minimally invasive treatment through the continued development of innovative products and new products. - FY2018-Q1Cited as achievedAnnual report
「The company has also successfully developed cardiovascular PTCA guidewires capable of treating CTOs, an area previously considered the domain of surgery.」
The successful development of PTCA guidewires capable of treating CTOs is again cited as evidence of the company’s contribution to expanding minimally invasive treatment. - FY2017Cited as achievedAnnual report
「Our group has contributed to expanding the use of PTCA treatment in the CTO field by developing and selling product groups, including PTCA guidewires and penetration catheters capable of treating CTOs and offering substantial product advantages unavailable from competitors.」
The company cites its track record of developing and selling products capable of treating CTOs as a contribution to the adoption of minimally invasive treatment. - FY2017-Q3Cited as achievedAnnual report
「The company has also successfully developed cardiovascular PTCA guidewires capable of treating CTOs, an area previously considered the domain of surgery.」
The successful development of PTCA guidewires capable of treating CTOs is cited as evidence of the company’s contribution to expanding minimally invasive treatment. - FY2016First statedAnnual report
「As a research and development-driven company, we will continue developing and commercializing highly competitive, innovative products and new products with enhanced functionality, thereby contributing to the adoption and advancement of minimally invasive treatment.」
The company intends to continue developing and commercializing products with advantages unavailable from competitors, including in the CTO field.